This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here



It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Mereo BioPharma Grp (MPH)

Mereo BioPharma Grp

Notice of General Meeting
RNS Number : 4154P
Mereo BioPharma Group plc
09 June 2020


Publication of Circular and Notice of General Meeting


London and Redwood City, Calif., June 9, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) announces that, further to the announcement regarding the completed Private Placement of $70 million (£56 million) (the "Fundraising") made on June 4, 2020, it has today published a circular (the "Circular") in connection with the Fundraising. 


The Circular contains a notice convening a General Meeting of the Company, at which certain resolutions in connection with the Fundraising will be put to shareholders. The meeting will be held at the 4th Floor, One Cavendish Place, London W1G 0QF, United Kingdom on 30 June 2020 at 11.00 a.m. (London time). In accordance with the UK Government's COVID-19 measures, ordinary shareholders are not expected to be allowed to attend the General Meeting in person, shareholders are therefore encouraged to submit their proxy vote electronically.


The Circular and the Notice of General Meeting will also be available for viewing on Mereo's website at .


Terms used in this announcement shall have the same meaning as those used in the Circular.


About Mereo BioPharma


Mereo BioPharma  is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo's strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to $300M in milestone payments. Mereo's lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD"). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study.  Following successful completion of Phase 2, Mereo is seeking partnerships for its two additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease ("AECOPD"), leflutrozole for the treatment of infertility and hypogonadotropic hypogonadism ("HH") in obese men. 


Additional Information


The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, General Counsel.


Mereo BioPharma Contacts:



+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer




Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo )

+44 (0)20 7894 7000

Phil Davies


Will Goode




Burns McClellan (US Public Relations Adviser to Mereo)

+01 (0) 212 213 0006

Lisa Burns


Steve Klass




FTI Consulting (UK Public Relations Adviser to Mereo )

 +44 (0)20 3727 1000

Simon Conway


Ciara Martin






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close